Dyne Therapeutics, Inc.
DYN· Nasdaq
DYNDyne Therapeutics, Inc.
Filed Jul 29, 2026 · 10-Q · 29 days after period end · 0001193125-26-323639
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$178.56M | -$110.86M | -$65.10M | -$64.90M |
| EPS Diluted | -$1.08 | -$0.97 | -$0.70 | -$1.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dyne Therapeutics, Inc. · CIK 1818794 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Jul 29, 2026 · 29 d after period end
